admin

admin

China Accepts First Line HER2 ADC Filing

China-originated regulatory signal: Hengrui disclosed on 29 October that NMPA accepted and placed its rezetecan trastuzumab application into priority review for first-line locally advanced or metastatic HER2-positive breast cancer, with or without pertuzumab. This…

China Accepts Sac TMT Lung Cancer Filing

China-source update: Kelun-Biotech’s Chinese-language newsroom listed on 28 October that CDE accepted a seventh sac-TMT indication filing for first-line PD-L1-negative, EGFR/ALK-negative nonsquamous NSCLC with pembrolizumab. The underlying Phase III OptiTROP-Lung06 data were reported earlier,…

SPNS2 Loss Exposes a MAPK Sensitive AML State

A peer-reviewed Nature Communications article published online 28 October links SPNS2 loss to altered sphingomyelin-rich membrane nanodomains, RAS localization and MAPK signaling in AML. Patient expression associations and mouse MEK-inhibitor sensitization suggest a context-specific…